These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2934743)

  • 1. Behavioral effects of cholecystokinin and its related peptides in rats.
    Itoh S; Katsuura G
    Prog Clin Biol Res; 1985; 192():139-45. PubMed ID: 2934743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversed behavioral effect of cholecystokinin after frontal decortication in rats.
    Itoh S; Katsuura G; Itoh T; Morimoto T
    Life Sci; 1994; 55(11):PL213-6. PubMed ID: 8072383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cholecystokinin and vasoactive intestinal peptide on locomotion and rearing in neofrontal decorticated rats.
    Katsuura G; Itoh S
    Prog Clin Biol Res; 1985; 192():147-50. PubMed ID: 4080707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
    Millington WR; Mueller GP; Lavigne GJ
    J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin tetrapeptide, proglumide and open-field behavior in rats.
    Hsiao S; Katsuura G; Itoh S
    Life Sci; 1984 May; 34(22):2165-8. PubMed ID: 6727557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fronto-cortical regulation of beta-endorphin actions in the rat.
    Itoh S; Katsuura G
    Peptides; 1985; 6(2):237-40. PubMed ID: 3162160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN; Stivers JA; Hommer DW; Skirboll LR; Paul SM
    J Pharmacol Exp Ther; 1986 Feb; 236(2):320-30. PubMed ID: 3003339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential antagonism by proglumide of various CCK-mediated effects in mice.
    Barbaz BS; Autry WL; Ambrose FG; Gerber R; Liebman JM
    Prog Clin Biol Res; 1985; 192():151-8. PubMed ID: 4080708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide in rat behavior after blockade of nitric oxide synthase by L-NAME.
    Hoły Z; Wiśniewski K
    Rocz Akad Med Bialymst; 1998; 43():250-70. PubMed ID: 9972062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats.
    Katsuura G; Itoh S
    Peptides; 1986; 7(5):809-14. PubMed ID: 3797342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of beta-endorphin effects by proglumide in rats.
    Katsuura G; Itoh S
    Eur J Pharmacol; 1985 Jan; 107(3):363-6. PubMed ID: 3156751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cholecystokinin-related peptides on retention of passive avoidance behaviour.
    Fekete M; Penke B; Telegdy G
    Acta Physiol Acad Sci Hung; 1982; 60(4):237-42. PubMed ID: 6314742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered responding to cholecystokinins and dopaminergic agonists following 6-hydroxydopamine treatment in rats.
    Hsiao S; Katsuura G; Itoh S
    Behav Neurosci; 1985 Oct; 99(5):853-60. PubMed ID: 3939625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by beta-endorphin and morphine administered intracerebroventricularly in mice.
    Suh HH; Tseng LF
    Eur J Pharmacol; 1990 Apr; 179(3):329-38. PubMed ID: 2142090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of rats. Part A.
    Wiśniewska RJ
    Pol J Pharmacol; 1998; 50(3):203-12. PubMed ID: 9861628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices.
    Ferraro L; Beani L; Trist D; Reggiani A; Bianchi C
    J Neurochem; 1999 Nov; 73(5):1973-81. PubMed ID: 10537055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of diabetic rats. Part B.
    Wiśniewska RJ
    Pol J Pharmacol; 1998; 50(3):213-23. PubMed ID: 9861629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.